Fig. 7: Intra-renal expressions of the CaSR and CaMKKβ-LKB1-AMPK-eNOS signaling pathways in db/m and db/db mice without or with cinacalcet treatment.

a and b Representative Western blot analyses of the CaSR, CaMMKα/β, total LKB1, phospho-Ser⁴²⁸ LKB1, total AMPK, phospho-Thr¹⁷² AMPK, PGC-1α, total eNOS, phospho-Ser¹¹⁷⁷ eNOS and β-actin expressions. Quantitative analyses of the results are shown (n = 3 in each experiments). *P < 0.05 and **P < 0.01 compared with other groups. c Intra-renal expressions of the SOD1 and SOD2 and d 24-h urinary 8-hydroxy-deoxyguanosine (8-OH-dG) and isoprostane concentrations in db/m and db/db mice without or with cinacalcet treatment. Representative Western blot analyses of the SOD1 and SOD2 (n = 3 in each groups) and 24-h urinary 8-OH-dG and isoprostane concentrations of the results are shown (n = 8 in each experiments). *P < 0.05 and **P < 0.01 compared with other groups. e Intra-renal Bcl-2/Bax ratio and f TUNEL-and WT-1-positive cells in the glomerulus in db/m and db/db mice without or with cinacalcet treatment. Representative Western blot analysis of the proapoptotic Bax, antiapoptotic Bcl-2 and β-actin expressions (n = 3 in each experiments) and immunohistochemical staining for TUNEL-positive cells (dark brown) are shown (original magnification, x400) (n = 8 in each groups). The quantitative analyses of the results are shown. *P < 0.05; **P < 0.01, and #P < 0.001 compared with other groups. g Intra-renal beclin 1 and LC3-II/LC3-I ratio and h LC3-II-PECAM-1, and i LC3-II-nephrin-positive cell in the glomerulus of db/m and db/db mice without or with cinacalcet treatment. Representative Western blot analysis of beclin-1, LC-3-I, LC3-II, and β-actin expressions are shown. The quantitative analyses of the results are shown (n = 3 in each groups). *P < 0.05 and **P < 0.01 compared with other groups